A multicenter, open-label, randomized phase 3 trial comparing the safety and efficacy of dovitinib (TKI258) versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angiogenic (VEGF-targeted and mTOR inhibitor) therapies Meeting Abstract
| Authors: | Motzer, R.; Sternberg, C. N.; Vogelzang, N.; Urbanowitz, G.; Cai, C.; Kay, A.; Escudier, B. |
| Abstract Title: | A multicenter, open-label, randomized phase 3 trial comparing the safety and efficacy of dovitinib (TKI258) versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angiogenic (VEGF-targeted and mTOR inhibitor) therapies |
| Meeting Title: | 10th International Kidney Cancer Symposium |
| Journal Title: | BJU International |
| Volume: | 109 |
| Issue: | Suppl.5 |
| Meeting Dates: | 2011 Oct 14-15 |
| Meeting Location: | Chicago, IL |
| ISSN: | 1464-4096 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2012-05-01 |
| Start Page: | 7 |
| End Page: | 8 |
| Language: | English |
| ACCESSION: | WOS:000303438400017 |
| PROVIDER: | wos |
| Notes: | --- - Meeting Abstract: 16 - 10th International Kidney Cancer Symposium - OCT 14-15, 2011 - Chicago, IL - "5" - SI - "Source: Wos" |
MSK Authors
-
1243Motzer